Quick Answer
CNBX Pharmaceuticals Inc. reported Cash and Equivalents of $15.1 thousand for fiscal year 2025.
CNBX Pharmaceuticals Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $15.1K | -42.8% |
| 2024 | $26.4K | -79.6% |
| 2023 | $129.7K | +10.4% |
| 2022 | $117.5K | -91.5% |
| 2021 | $1.39M | +78.3% |
| 2020 | $777.6K | +192.4% |
| 2019 | $266.0K | -80.9% |
| 2018 | $1.39M | +0.0% |
| 2017 | $1.39M | +7186.1% |
| 2016 | $19.1K | -24.2% |
| 2015 | $25.2K | -74.5% |
| 2014 | $98.8K | — |
| 2013 | $0.00 | — |
| 2012 | $0.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| November 30, 2025 | $7.7K | -55.6% | -49.0% |
| August 31, 2025 | $15.1K | -42.8% | +10.7% |
| May 31, 2025 | $13.6K | -81.4% | -70.1% |
| February 28, 2025 | $45.7K | +23.0% | +163.4% |
| November 30, 2024 | $17.3K | -78.8% | -34.4% |
| August 31, 2024 | $26.4K | -79.6% | -64.0% |
| May 31, 2024 | $73.4K | +66.3% | +97.6% |
| February 29, 2024 | $37.1K | -22.2% | -54.5% |
- CNBX Pharmaceuticals Inc. showed a decrease of -42.8% in Cash and Equivalents compared to the prior fiscal year.
- The most recent figure is from CNBX Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on December 1, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: